AdvSM is a rare condition indicated by the uncontrolled accumulation of neoplastic mast...
AstraZeneca studies Fasenra in three new trials for skin diseases
AstraZeneca has started three new clinical trials to evaluate monoclonal antibody Fasenra for the treatment of eosinophil-driven skin diseases.
Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC
riginally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin formulated with Sodium N-[8-(2-hydroxy benzoyl) amino] caprylate (SNAC).
Annexon launches Phase 1b study of ANX-005 in combination with IVIG in subjects with Guillain-Barré syndrome
Guillain-Barré syndrome is a rare autoimmune neurological disorder in which the immune system attacks the peripheral nervous system.
Blueprint’s Phase II avapritinib sparks concerns on risk-benefit profile
AdvSM is a rare condition indicated by the uncontrolled accumulation of neoplastic mast cells (MCs) in various organs.
Sanofi’s trial of sutimlimab meets primary and secondary endpoints
Sanofi has reported positive results from a pivotal Phase III trial of sutimlimab for the treatment of people with cold agglutinin disease (CAD), a serious, chronic, rare blood disorder.
Intercept’s Phase II-ready Ocaliva/bezafibrate has mixed experts views in primary biliary cholangitis
Primary biliary cholangitis is a long-term, autoimmune condition which affects the liver.
Evaluating NICE guidelines in regards to cannabis-based medicinal products targeting pain
Campaigners argue the new regulations are not extensive enough where the recommendation of cannabis-based medicine for pain is concerned.
Biogen’s Phase II LILAC trial for lupus treatment meets goals
Biogen has reported that the Phase II LILAC clinical trial of BIIB059 has met the primary endpoints in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).
VFMCRP and ChemoCentryx report positive data for avacopan
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx have reported positive data from the Phase III clinical trial of avacopan to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Nektar and Alkermes data could translate into a resurgence of IL-2 agonists
Data for modified IL-2 selective receptor agonists, NKTR-214 and ALKS 4230, was presented at the 2019 Society for Immunotherapy of Cancer (SITC) conference.